Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC

Chemotherapy

Volumn 43, Issue 4, 1997, Pages 239-244

  Deguchi, Takashi ^a   Yasuda, Mitsuru ^a   Nakano, Masahiro ^a   Ozeki, Shigehiko ^a   Kanematsu, Emiko ^a   Fukuda, Hideyuki ^b   Maeda, Shin Ichi ^c   Saito, Isao ^d   Kawada, Yukimichi ^a  

^a GIFU UNIVERSITY   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

^c TOYOTA MEMORIAL HOSPITAL   (Japan)

^d TOKYO KYOSAI HOSPITAL   (Japan)

Author keywords

AM 1155; Gyra; Neisseria gonorrhoeae; Parc; Quinolone resistance

Indexed keywords

AGAR; ANTIBIOTIC AGENT; CIPROFLOXACIN; FLEROXACIN; GATIFLOXACIN; QUINOLONE; TOSUFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; ESCHERICHIA COLI; GENE MUTATION; GONORRHEA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030918114     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239573     Document Type: Article

References (23)

1. Centers for Disease Control: 1993 Sexually transmitted diseases treatment guidelines. Morbid Mortal Weekly Rep 1993;42:57-59.
2. Gorwitz RJ, Nakashima AK, Mora JS, Knapp JS: Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae- United States, 1988-1991. Morbid Mortal Weekly Rep 1993;42:29-39.
3. Echols RM, Heyd A, O’Keeffe BJ, Schacht P: Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: A worldwide summary. SexTransm Dis 1994;21:345-352.
4. Zenilman JM, Neumann T, Patton M, Reichart C: Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin aginst 200 isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1993;37:2244-2246.
5. Gransden WR, Warren CA, Phillips I, Hodgcns M, Barlow D: Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990;335:51.
6. Jephcott AE, Turner A: Cirpofloxa-cin resistance in gonococci. Lancet 1990;335:165.
7. Tapsall JW, Shultz TR, Lovett R, Munro R: Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Med J Aust 1992; 156: 143.
8. Tanaka M, Kumazawa J, Matsumo-to T, Kobayashi I: High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitourin Med 1994;70:90-93.
9. Centers for Disease Control: Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolone -Ohio and Hawaii, 1992-1994. Morbid Mortal Weekly Rep 1994;43: 325-327.
10. Birley H, McDonald P, Carey P: High level ciprofloxacin resistance in Neisseria gonorrhoeae. Genitourin Med 1994;70:292-293.
11. Belland RJ, Morrison SG, Ison C, Huang WM: Neisseria gonorrhoeae acquires mutations in analogous regions ofgyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 1994;14:371-380.
12. Corkill JE, Percival A, Lind M: Reduced uptake of ciprofloxacin in a resistant strain of Neisseria gonorrhoeae and transformation of resistance to other strains. J Antimicrob Chemother 1991;28:601-604.
13. Dcguchi T, Yasuda M, Asano M, Tada K, Iwata H, Komeda H, Ezaki T, Saito I, Kawada Y: DNA gyrase mutations in quinolone-rcsistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995;39:561-563.
14. Stein DC, Danaher RJ, Cook TM: Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 1991;35:622-626.
15. Tanaka M, Fukuda H, Hirai K. Ho-saka M, Matsumoto T. Kumazawa J: Reduced uptake and accumulation of norfloxacin in resistant strains of Neisseria gonorrhoeae isolated in Japan. Genitourin Med 1994;70:253-255.
16. Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, Kawada Y: Quinolone-resistant Neisseria gonorrhoeae: Correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomer-ase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 1996;40:1020-1023.
17. Hosaka M, Yasue T, Fukuda H, Tontizawa H, Aoyama H, Hirai K: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992; 36:2108-2117.
18. Yoshida H, Bogaki M. Nakamura M, Nakamura S: Quinolone resistance determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990;34:1271-1272.
19. National Committee for Clinical Laboratory' Standards: Approved standard M7-A3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Villanova, National Committee for Clinical Laboratory Standards, 1993.
20. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H: Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-me-thoxy quinolone, in humans. Antimicrob Agents Chemother 1995;29: 2635-2640.
21. Ooie T, Machida M, Kusajima H, Ishida R, Uchida H, Nishino K: Pharmacokinetics of AM-1155, a new quinolone, in laboratory' animals (abstr. 386). Program and Abstracts 30th Interscience Conf Antimicrobial Agents and Chemotherapy. Washington. American Society for Microbiology, 1990.
22. Kobayashi H, Shimura M: Phase I study with Bay 09867 (ciprofloxacin). Chemotherapy (Tokyo) 1985; 33(suppl 7): 140-170.
23. Tapsall JW, Limnios EA, Thacker C, Donovan B, Lynch SD, Kirby LJ, Wise KA, Carnody CJ: High-level quinolone resistance in Neisseria gonorrhoeae: A report of two cases. Sex Transm Dis 1995;22:310-311.